Antibiotic Selection in Pediatric Febrile Neutropenia

Emine ZENGİNa , Sema AYLAN GELENa

aKocaeli University Faculty of Medicine, Division of Pediatric Hematology, Kocaeli, Türkiye

ABSTRACT

Fever in a pediatric cancer patient with neutropenia may be the first sign of a life-threatening condition. Treatment of febrile neutropenia should be individualized, taking into account the underlying hematologic disease, the chemotherapy regimen received, the duration of neutropenia, local epidemiological data and diagnostic resources at the center, and the daily bedside evaluation of the patient. When a patient develops fever, an anti-pseudomonal antibiotic regimen, most likely effective against Gram-negative bacteria, should be started immediately. The continuation and duration of treatment should be adjusted according to clinical and microbiological parameters.

Keywords: Febrile neutropenia; child; antimicrobial stewardship

Referanslar

  1. Arif T, Phillips RS. Updated systematic review and meta-analysis of the predictive value of serum biomarkers in the assessment and management of fever during neutropenia in children with cancer. Pediatr Blood Cancer. 2019;66(10):e27887. [Crossref]
  2. Spelberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action fort he medical community from the Infectious Disease Socieity of America. Clin Infect Dis. 2008;46:155-64. [Crossref]
  3. Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for emprical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013;98:1826-35. [Crossref]
  4. Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, Beauchemin M, et al. Guideline for the management of fever and neutropenia in children with cancer andhematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol. 2017;35(18):2082-94. [Crossref]
  5. Rodríguez L, Ethier MC, Phillips B, Lehrnbecher T, Doyle J, Sung L. Utility of peripheral blood cultures in patients with cancer and suspected blood stream infections: a systematic review. Support Care Cancer. 2012;20(12):3261-7. [Crossref]
  6. Sateren WB, Trimble EL, Abrams J, Brawley O, Breen N, Ford L, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programsaffect accrual to cancer treatment trials. J Clin Oncol. 2002;20(8):2109-17. [Crossref]
  7. Phillips B, Selwood K, Lane SM, Skinner R, Gibson F, Chisholm JC, et al. Variation in policies for the management of febrile neutropenia in United Kingdom children's cancer study group centres. Arch Dis Child. 2007;92(6):495-8. [Crossref]
  8. Fisher BT, Gerber JS, Leckerman KH, Seif AE, Huang YS, Li Y, et al. Variation in hospital antibiotic prescribing practices for childrenwith acute lymphoblastic leukemia. Leuk Lymphoma. 2013;54(8):1633-9. [Crossref]
  9. Guido M, Quattrocchi M, Zizza A. Molecular approaches in the diagnosis of sepsis in neutropenic patients with haematological malignances. J Prev Med Hyg. 2012;53(2):104-8.
  10. Torres JP, De la Maza V, Kors L, et al. Respiratory viral infections and coinfections in children with cancer, fever and neutropenia: clinical outcome of infections caused by different respiratory viruses. Pediatr Infect Dis J. 2016;35(9):949-54. [Crossref]
  11. Phillips RS, Wade R, Lehrnbecher T, Stewart LA, Sutton AJ. Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Med. 2012;10(1):6 [Crossref]
  12. Haeusler GM, Carlesse F, Phillips RS. An updated systematic review and meta-analysis of the predictive value of serum biomarkers in the assessment of fever during neutropenia in children with cancer. Pediatr Infect Dis J. 2013;32(10):e390-6. [Crossref]
  13. Wang SS, Mechinaud F, Thursky K, Cain T, Lau E, Haeusler GM. The clinical utility of fluorodeoxyglucose-positron emission tomography for investigation of fever in immunocompromised children. J Paediatr Child Health. 2018;54(5):487-92. [Crossref]
  14. Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol. 2006;24:4129-34. [Crossref]
  15. Phillips RS, Sung L, Amman RA, et al. Predicting microbiologically defined infection in febrile neutropenic episodes in children: global individual participant data multivariable meta-analysis. Br J Cancer. 2016;114:623-30. [Crossref]
  16. Haeusler GM, Thursky KA, Slavin MA, et al. External validation of six pediatric fever and neutropenia clinical decision rules. Pediatr Infect Dis J. 2018; 37:329-35. [Crossref]
  17. Alexander SW, Wade KC, Hibberd PL, Parsons SK. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol. 2002;24:38e42. [Crossref]
  18. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-93. [Crossref]
  19. Koenig C, Schneider C, Morgan JE, Ammann RA, Sung L, Phillips B. Association of time to antibiotics and clinical outcomes in patients with fever and neutropenia during chemotherapy for cancer: a systematic review. Support Care Cancer. 2020;28(3):1369-83. [Crossref]
  20. Robinson PD, Lehrnbecher T, Phillips R, et al. Strategies for empiric management of pediatric fever and neutropenia in patients with cancer and hematopoietic stem-cell transplantation recipients: a systematic review of randomized trials. J Clin Oncol. 2016;34:2054-60. [Crossref]
  21. Mikulska M, Averbuch D, Tissot F, et al. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J Infect. 2018;76:20-37. [Crossref]
  22. Alexander S, Fisher BT, Gaur AH, Dvorak CC, Villa Luna D, Dang H, et al. Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation: a randomized clinical trial. JAMA. 2018;320(10):995-1004. [Crossref]
  23. Levene I, Castagnola E, Haeusler GM. Antibiotic-resistant gram-negative blood stream infections in children with cancer: a review of epidemiology, risk factors, and outcome. Pediatr Infect Dis J. 2018;37:495-8. [Crossref]
  24. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol. 2018;36(14):1443-53. [Crossref]
  25. Buchanan GR. Aproach to treatment of the febrile cancer patient with low-risk neutropenia. Hematol Oncol Clin North Am. 1993;7:919-35. [Crossref]
  26. Pizzo PA, Robichaud KJ, Gill FA, et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. AM J Med. 1982;72:101-11. [Crossref]
  27. Stern A, Carrara E, Bitterman R, Yahav D, Leibovici L, Paul M. Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer. Cochrane Database Syst Rev. 2019;1:CD012184. [Crossref]
  28. Maschmeyer G. Invasive fungal disease: better survival through early diagnosis and therapeutic intervention. Expert Rev Anti Infect Ther. 2011;9:279-81. [Crossref]
  29. Lehrnbecher T, Becker K, Groll AH. Current algorithms in fungal diagnosis in the immunocompromised host. Methods Mol Biol. 2017;1508:67-84. [Crossref]
  30. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol. 1997;15:139-47. [Crossref]
  31. Erman M, Akova M, Akan H, Korten V, Ferhanoglu B, Koksal I, et al. Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study. Scand J Infect Dis. 2001;33:827-31. [Crossref]
  32. Tamura K, Imajo K, Akiyama N, Suzuki K, Urabe A, Ohyashiki K, et al. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. Clin Infect Dis. 2004;39 Suppl 1:S15-S24. [Crossref]